Investor profile for Third Rock Ventures: stage-based planning range, investment stages, sector focus, portfolio companies, sources, and verification status. Part of the Venture Capital Tracker directory.
Third Rock Ventures
stages, portfolio and investment profile
Boston-based life sciences firm that co-founds and builds biotechnology companies alongside scientists, advancing breakthrough therapeutics from company creation through clinical development.
Keep track of Third Rock Ventures
Save this profile to your VCT watchlist for a quick return.
Stage fit, check size, thesis, and how founders typically approach this firm — based on public sources and our directory.
Third Rock leads seed and Series A rounds in companies it co-founds. Our directory lists Seed and Series A coverage; the firm typically stays involved from inception through clinical milestones.
Third Rock does not publish a standard check-size range. As a company-creation biotech firm, initial commitments are sized to build teams and advance programs to key clinical inflection points — amounts vary by therapeutic area and development plan.
Third Rock is headquartered in Boston, Massachusetts, in the heart of the Cambridge-Boston biotech cluster. Portfolio companies are U.S.-focused; the firm invests nationally where scientific talent and development infrastructure align.
Third Rock focuses exclusively on biotechnology and life sciences — therapeutics, drug discovery, and related platforms. Our directory tags biotech-life-sciences. The firm is known for co-founding companies with academic and industry scientists rather than passive seed investing.
Third Rock routinely leads and often initiates rounds in companies it helps create. The model is hands-on company building — partners embed with founding teams from day one.
Directory startups listing Third Rock include Insitro, Maze Therapeutics, and BioAge Labs — see /startup/insitro, /startup/maze-therapeutics, and /startup/bioage-labs.
Third Rock's model centers on partnering with scientists and operators to build companies from scratch. Review thirdrockventures.com for the team's therapeutic focus. Warm introductions from scientific collaborators or co-investors are the standard path; the firm does not promote a public cold-pitch inbox.
See 2026-boston-vc-2026-biotech-dominance-playbook for Third Rock's role among Boston's top therapeutics-creation firms.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
